The number of facilities weighing an assessment of risk for HDs as a review point during the formulary adoption process remains steady at 77%.

While the number of facilities including drugs beyond the NIOSH HD list when developing their facility’s HD list is slowly trending upward, just under one-quarter of facilities currently take this approach.

Given that two-thirds of survey respondents are handling investigational drugs, it is important to have a policy for classifying these products.

Just one-quarter of facilities handling investigational drugs assign all of these products to be handled as HDs utilizing all relevant precautions. The more common approach is to rely on the study sponsor to identify HD handling requirements.